Plasma myeloperoxidase levels correlate with hepatocellular carcinoma in chronic hepatitis C

详细信息    查看全文

• 作者：Rodrigo Feliciano do Carmo ; D¨¦bora Bezerra de Almeida ; Dayse C¨¦lia Barbosa Lins Aroucha ; Luydson Richardson Silva Vasconcelos ; Adriano Claudio Pereira de Moraes ; Maria do Socorro de Mendon?a Cavalcanti ; Clarice Neuenschw ; er Lins de Morais ; Leila Maria Moreira Beltr?o Pereira ; Patr¨ªcia Moura
• 关键词：HCV ; Hepatitis C virus ; CH ; chronic hepatitis ; MF ; mild fibrosis ; SV ; severe fibrosis ; HCC ; hepatocellular carcinoma ; AFP ; alpha-fetoprotein ; ROS ; reactive oxygen species ; MPO ; myeloperoxidase ; HIV ; human immunodeficiency virus ; ELISA ; enzyme-linked immun
• 刊名：Human Immunology
• 出版年：2012
• 出版时间：November, 2012
• 年：2012
• 卷：73
• 期：11
• 页码：1127-1131
• 全文大小：284 K

文摘

Myeloperoxidase (MPO) is an enzyme responsible for generating hypochlorous acid and reactive oxidants that may lead to liver injury and cancer in hepatitis C (HCV) infection. MPO expression level is regulated by a polymorphism in the promoter region ?463 of MPO gene. In the current study, MPO plasma levels and the G-463A MPO polymorphism were determined in 158 chronically HCV infected patients with and without hepatocellular carcinoma (HCC). MPO plasma levels were determined using a commercially ELISA kit. The G-463A MPO polymorphism was accessed by real time PCR using TaqMan probes. The MPO plasma levels of patients with HCV-HCC were higher in comparison to patients with chronic hepatitis or with those patients with severe fibrosis (p = 0.01 and p = 0.04, respectively). The MPO G-463A polymorphism was not associated with HCV outcome. These findings suggest MPO levels monitoring may be a potential biological marker to HCC screening in patients with HCV.